Breaking News Instant updates and real-time market news.

ONCE

Spark Therapeutics

$55.95

-21.68 (-27.93%)

12:45
08/07/18
08/07
12:45
08/07/18
12:45

Spark Therapeutics price target lowered to $55 from $74 at Leerink

  • 07

    Aug

  • 10

    Sep

ONCE Spark Therapeutics
$55.95

-21.68 (-27.93%)

07/19/18
07/19/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Underperform from Hold at Needham with analyst Rajvindra Gill saying the stock remains overvalued in spite of its 16% decline from the the June 2017 peak. 2. Procter & Gamble (PG) downgraded to Neutral from Buy at UBS with analyst Steven Strycula saying the company's reinvestment cycle limits earnings and stock upside. 3. Terex (TEX) downgraded to Market Perform from Outperform at Wells Fargo with analyst Andrew Casey saying his crane check was good but not great, with demand appearing to sequentially flatten. 4. Spark Therapeutics (ONCE) downgraded to Sector Perform from Outperform at RBC Capital with analyst Kennen MacKay saying that after a strong run-up in the stock price driven by lofty expectations for the ongoing Phase 1/2 trial of SPK-8011 in patients with hemophilia, achieving mean FVIII expression levels of 30-55% anticipated by the Street could prove "challenging" as "data to date has not indicated clear dose responsiveness." 5. Hyatt (H) downgraded to Hold from Buy at Berenberg with analyst El Kassir saying Hyatt continues to benchmark well on its pipeline, however, there is little scope for future growth to accelerate from current levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/07/18
PIPR
08/07/18
NO CHANGE
Target $120
PIPR
Overweight
BioMarin competitive positioning 'improved measurably,' says Piper Jaffray
Spark Therapeutics' (ONCE) update this morning for hemophilia A candidate SPK-8011 was disappointing both efficacy- and safety-wise, Piper Jaffray analyst Christopher Raymond tells investors in a research note titled "Spark Fails to Ignite; Valrox Competitive Positioning Just Improved Measurably." He believes the news "goes a long way" to putting this potential threat to BioMarin (BMRN) "to bed." The analyst is incrementally positive on BioMarin's competitive positioning in hemophilia A and keeps an Overweight rating on the shares with a $120 price target. The Spark data compares unfavorably to BioMarin's valrox, Raymond writes. He remains a buyer of BioMarin with an Overweight rating and $120 price target. The stock in premarket trading is up $5.55 to $103.50.
08/07/18
SBSH
08/07/18
UPGRADE
SBSH
Buy
Spark Therapeutics upgraded to Buy from Neutral at Citi
08/07/18
SBSH
08/07/18
UPGRADE
SBSH
Buy
Citi upgrades Spark Therapeutics to Buy with shares down nearly 30%
Citi analyst Mohit Bansal upgraded Spark Therapeutics to Buy from Neutral amid today's post-earnings selloff. The analyst maintains an $85 price target for the shares. The company's update this morning on its hemophilia A gene therapy was "incrementally positive and better than our expectations," Bansal tells investors in a research note. The analyst feels investors should not be too concerned about the immune flare in two patients as he thinks these patients could be managed with prophylactic use of steroids. Other gene therapy players are using prophylactic steroids and it was a bit surprising that Spark did not use prophylactic steroid in the first place, the analyst writes. He views today's selloff as a buying opportunity saying the data in five of seven patients are better than his expectations. Bansal notes that Spark will employ a prophy strategy going forward. The analyst also views the company as a potential takeover candidate. He pegs Spark's buyout valuation at $130 per share. The stock in midday trading is down 29%, or $22.49, to $55.12.

TODAY'S FREE FLY STORIES

OIH

Oil Services Holders Trust

$18.87

0.37 (2.00%)

14:50
11/21/18
11/21
14:50
11/21/18
14:50
Options
Active trading in VanEck Vectors Oil Services 20-strike calls »

Active trading in VanEck…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,529.99

34.39 (2.30%)

14:50
11/21/18
11/21
14:50
11/21/18
14:50
Periodicals
NYC officials say half of Queens Amazon jobs won't be in tech, WSJ says »

New York City officials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 04

    Dec

SQM

SQM

$43.70

1.825 (4.36%)

14:49
11/21/18
11/21
14:49
11/21/18
14:49
Options
SQM options imply 8.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:45
11/21/18
11/21
14:45
11/21/18
14:45
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

CBFV

CB Financial Services

$25.79

(0.00%)

14:42
11/21/18
11/21
14:42
11/21/18
14:42
Hot Stocks
CB Financial Services increases dividend by 4.5% to 23c per share »

CB Financial Services,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$32.94

4.87 (17.35%)

14:28
11/21/18
11/21
14:28
11/21/18
14:28
Hot Stocks
CD&R Group to buy additional shares in Beacon Roofing »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

NTN

NTN Buzztime

$2.70

-0.1 (-3.57%)

14:26
11/21/18
11/21
14:26
11/21/18
14:26
Hot Stocks
Northstar reports 10.33% stake in NTN Buzztime »

On November 21, Northstar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:23
11/21/18
11/21
14:23
11/21/18
14:23
Conference/Events
The U.S. Commodity Futures Trading Commission to hold a podcast »

The Commodity Futures…

RHHBY

Roche

$0.00

(0.00%)

, ABBV

AbbVie

$85.75

-2.35 (-2.67%)

14:18
11/21/18
11/21
14:18
11/21/18
14:18
Hot Stocks
Roche announces FDA grants accelerated approval for Venclexta combo »

Roche (RHHBY) announced…

RHHBY

Roche

$0.00

(0.00%)

ABBV

AbbVie

$85.75

-2.35 (-2.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

  • 03

    Dec

  • 24

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
11/21/18
11/21
14:17
11/21/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$85.70

-2.4 (-2.72%)

, RHHBY

Roche

$0.00

(0.00%)

14:16
11/21/18
11/21
14:16
11/21/18
14:16
Hot Stocks
AbbVie says FDA grants accelerated approval to Venclexta-azacitidine combo »

AbbVie (ABBV) announced…

ABBV

AbbVie

$85.70

-2.4 (-2.72%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

  • 03

    Dec

  • 24

    Dec

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
11/21/18
11/21
14:16
11/21/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPP

WPP

$54.99

1.4 (2.61%)

14:15
11/21/18
11/21
14:15
11/21/18
14:15
Periodicals
Martin Sorrell to poach senior executive from WPP, Sky News reports »

Martin Sorrell is to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

TGT

Target

$69.10

0.05 (0.07%)

14:10
11/21/18
11/21
14:10
11/21/18
14:10
Options
Target calls lead puts 3:1 after a big drop in shares »

Target calls lead puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

HWBK

Hawthorn Bancshares

$22.71

(0.00%)

14:08
11/21/18
11/21
14:08
11/21/18
14:08
Hot Stocks
Ategra stake in Hawthorn Bancshares falls to 4.97% »

As of November 20, Ategra…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAM

I-AM Capital

$10.00

(0.00%)

14:04
11/21/18
11/21
14:04
11/21/18
14:04
Hot Stocks
I-AM Capital announces closing of transaction with SMAAASH Entertainment »

Smaaash Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBD

Banco Bradesco

$9.60

0.23 (2.45%)

14:00
11/21/18
11/21
14:00
11/21/18
14:00
Options
Longer-term put buyer in Banco Bradesco »

Longer-term put buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SPY

SPDR S&P 500 ETF Trust

$266.76

2.64 (1.00%)

, SPX

S&P 500

$0.00

(0.00%)

13:56
11/21/18
11/21
13:56
11/21/18
13:56
Periodicals
Hedge funds get battered in October and are down for year, CNBC says »

According to a CNBC…

SPY

SPDR S&P 500 ETF Trust

$266.76

2.64 (1.00%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIPS

Vipshop

$5.54

0.07 (1.28%)

13:50
11/21/18
11/21
13:50
11/21/18
13:50
Options
Aggressive call buy in Vipshop »

Aggressive call buy in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

13:50
11/21/18
11/21
13:50
11/21/18
13:50
General news
Treasury Action: yields remain only marginally firmer »

Treasury Action: yields…

PFE

Pfizer

$43.23

-0.3 (-0.69%)

13:41
11/21/18
11/21
13:41
11/21/18
13:41
Hot Stocks
Pfizer says FDA approves DAURISMO for adults with newly-diagnosed AML »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

  • 10

    Dec

EFA

iShares MSCI EAFE Index Fund

$62.35

1.05 (1.71%)

13:40
11/21/18
11/21
13:40
11/21/18
13:40
Options
Call buying in iShares Emerging Markets Fund and iShares MSCI EAFA Fund »

Call buying in iShares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

13:30
11/21/18
11/21
13:30
11/21/18
13:30
Options
Vix calls lead puts 4:1 as the index drops 9% »

Vix calls lead puts 4:1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKRX

Akorn

$6.95

0.18 (2.66%)

13:25
11/21/18
11/21
13:25
11/21/18
13:25
Options
Akorn call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

OMED

OncoMed

$1.37

(0.00%)

13:22
11/21/18
11/21
13:22
11/21/18
13:22
Hot Stocks
OncoMed awarded European patent for method for making heteromultimeric molecules 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.